New immunotherapies using cancer antigens recognized by T-cells have recently been developed and a variety of phase I clinical trals has been conducted in the US and Europe. An anti-tumor effect has already been observed in some protocols. However, many questions still remain to establish effective immunotherapies for cancer. Key points which were raised in the research on immunotherapies against melanoma are discussed in this article.
|出版ステータス||Published - 1999 6月 26|
ASJC Scopus subject areas